The Crossfire team attended this year’s American Association for Cancer Research (AACR) annual meeting with three posters.
On Tuesday the Crossfire team unveiled its highly innovative degrader-based payload targeting an essential cell cycle kinase. Its sophisticated design is expected to dramatically
The Crossfire team will present 3 posters at the American Association for Cancer Research (AACR) annual meeting 2024. We will highlight the latest data on our best-in-class macrocyclic BTK inhibitor CFON-026, our novel Degrader Antibody Conjugate (DAC) technology, and our
Today Crossfire Oncology B.V. (Crossfire) has entered its brand-new state-of-the-art chemistry and molecular biology laboratories at the Marie Curie Building (Pivot Park, Oss). The new facilities will enable Crossfire to expand their activities in developing kinase Degrader Antibody Conjugates (DACs)
NTRC Therapeutics, a biotech company specialized in the research and development of kinase inhibitors and degraders, will continue under the name Crossfire Oncology.
Founded in 2011 as Netherlands Translational Research Center, NTRC originally pursued a dual business model providing services to